CAS 284461-73-0
:Sorafénib
Description :
Sorafénib est un inhibiteur de la tyrosine kinase à petites molécules principalement utilisé dans le traitement de certains types de cancer, y compris le carcinome à cellules rénales et le carcinome hépatocellulaire. Sa formule chimique est C21H16ClF2N3O3, et il présente une structure complexe qui comprend un cycle pyridine, un groupe phényle et un groupe urée. Sorafénib fonctionne en inhibant plusieurs kinases impliquées dans la prolifération des cellules tumorales et l'angiogenèse, ciblant spécifiquement la kinase RAF et diverses kinases de tyrosine réceptrices. Cette approche multi-cible aide à interrompre les voies de signalisation qui favorisent la croissance et la métastase du cancer. Sorafénib est généralement administré par voie orale et a une biodisponibilité modérée, sa pharmacocinétique étant influencée par des facteurs tels que l'apport alimentaire. Les effets secondaires courants comprennent la fatigue, la diarrhée et les réactions cutanées. En raison de son mécanisme d'action et de ses applications thérapeutiques, Sorafénib représente une avancée significative dans les thérapies ciblées contre le cancer, bien que son utilisation puisse être limitée par le développement de résistance et la nécessité d'une surveillance attentive des patients.
Formule :C28H24ClF3N4O6S
InChI :InChI=1/C21H16ClF3N4O3.C7H8O3S/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25;1-6-2-4-7(5-3-6)11(8,9)10/h2-11H,1H3,(H,26,30)(H2,28,29,31);2-5H,1H3,(H,8,9,10)
Code InChI :InChIKey=MLDQJTXFUGDVEO-UHFFFAOYSA-N
SMILES :O(C=1C=C(C(NC)=O)N=CC1)C2=CC=C(NC(NC3=CC(C(F)(F)F)=C(Cl)C=C3)=O)C=C2
Synonymes :- 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-
- 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
- 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide 4-methylbenzenesulfonate
- 4-[4-[[4-Chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
- 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-Pyridinecarboxamide
- Bay 43-9006
- N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
- Nevaxar
- Sorafenib base
- Sorafenib
- SORAFENIB TOLSYLATE
- Sorafenib free base for research
- SORAFENIB-D3
- SORAFENIB MESYLATE
- BAY-43-900
- Sorafenib Tosylate(TINIBS)
- N-[4-Chloro-3-(trifluoromethyl)phenyl]-({4-[2-(N-methyl-carbamoyl)(4-pyridyloxy)]phenyl}amino)-carboxamide
- RAF1 KINASE INHIBITOR II
- SORAFENIB(FORR&DONLY)
- Sorafenib Tosylate for research
- Voir plus de synonymes
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
14 produits concernés.
Sorafenib
CAS :Formule :C21H16ClF3N4O3Degré de pureté :>98.0%(T)(HPLC)Couleur et forme :White to Light yellow powder to crystalMasse moléculaire :464.834-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
CAS :Formule :C21H16ClF3N4O3Degré de pureté :99%Couleur et forme :SolidMasse moléculaire :464.8249Sorafenib
CAS :Sorafenib (Bay 43-9006) is a multikinase inhibitor that inhibits Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6/22/90/15/20/20/57Formule :C21H16ClF3N4O3Degré de pureté :98% - 99.89%Couleur et forme :SolidMasse moléculaire :464.82Sorafenib
CAS :SorafenibFormule :C21H16ClF3N4O3Degré de pureté :98%Couleur et forme : white solidMasse moléculaire :464.82g/molSorafenib
CAS :Formule :C21H16ClF3N4O3Degré de pureté :≥ 95.0%Couleur et forme :White, off-white or light-yellow solidMasse moléculaire :464.83Sorafenib
CAS :Formule :C21H16ClF3N4O3Couleur et forme :White To Off-White SolidMasse moléculaire :464.83Sorafenib
CAS :Produit contrôléFormule :C21H16ClF3N4O3Couleur et forme :NeatMasse moléculaire :464.82Sorafenib-d4
CAS :Produit contrôléFormule :C21H12D4ClF3N4O3Couleur et forme :NeatMasse moléculaire :468.85Sorafenib - Bio-X ™
CAS :<p>Sorafenib is a drug that belongs to the class of multikinase inhibitors. It inhibits a number of kinases, including the Mcl-1 protein, which is involved in apoptosis along with blocking picolinic acid (PA), an endogenous metabolite involved in apoptosis signal transduction. Sorafenib also binds to epidermal growth factor receptor (EGFR) on the surface of cancer cells, inhibiting the production of proteins that are required for angiogenesis, thus blocking the formation of new blood vessels. Sorafenib may also inhibit P-glycoprotein (Pgp) activity. Overall, these cytotoxic effects give Sorafenib anti-tumor properties, inhibiting angiogenesis and cellular transformation, which are the two main processes of tumor growth and metastasis. Sorafenib has been shown to be effective against a range of solid tumors such as breast, prostate and lung cancers and is also used for the treatment of metastatic colorectal cancer and renal cell carcinoma. A combination therapy group found that sorafenib was more effective when used with interferon alfa-2b for the treatment of advanced renal cell carcinoma. Sorafenib also has the potential for drug interactions with other drugs that are metabolized by cytochrome P450 enzymes.<br>Sorafenib is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready to use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.</p>Formule :C21H16ClF3N4O3Degré de pureté :Min. 98%Couleur et forme :PowderMasse moléculaire :464.82 g/molSorafenib
CAS :<p>Sorafenib is a drug that belongs to the class of multikinase inhibitors. It inhibits a number of kinases, including the Mcl-1 protein, which is involved in apoptosis along with blocking picolinic acid (PA), an endogenous metabolite involved in apoptosis signal transduction. Sorafenib also binds to epidermal growth factor receptor (EGFR) on the surface of cancer cells, inhibiting the production of proteins that are required for angiogenesis, thus blocking the formation of new blood vessels. Sorafenib may also inhibit P-glycoprotein (Pgp) activity. Overall, these cytotoxic effects give Sorafenib anti-tumor properties, inhibiting angiogenesis and cellular transformation, which are the two main processes of tumor growth and metastasis. Sorafenib has been shown to be effective against a range of solid tumors such as breast, prostate and lung cancers and is also used for the treatment of metastatic colorectal cancer and renal cell carcinoma. A combination therapy group found that sorafenib was more effective when used with interferon alfa-2b for the treatment of advanced renal cell carcinoma. Sorafenib also has the potential for drug interactions with other drugs that are metabolized by cytochrome P450 enzymes.</p>Formule :C21H16ClF3N4O3Degré de pureté :Min. 98.0 Area-%Couleur et forme :White PowderMasse moléculaire :464.82 g/mol
![4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb%2FDA0039KS.jpg&w=3840&q=75)
